Luminal HER2 negative cancer (n = 58) changed to luminal HER2 positive in the metastases of four patients (6.9%), to non-luminal HER2 positive in two patients (3.4%) and to triple negative in eight patients (13.8%) (Fig. 4). The gene discussed is ERBB2; the disease is cancer.